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5Liebe FID-Mitglieder
Liebe Mitglieder der Schweizerischen Gesellschaft für Endokrinologie und Diabetologie
Liebe Diabetes-Interessierte
Meinen Mitarbeitern und mir ist es eine grosse Freude, das 31. Donau-Symposium in Bern zu or-
ganisieren und Sie vom 30.6. bis 2.7.2016 zu diesem Symposium empfangen zu dürfen!
Erstmals finden der Kongress der Zentraleuropäischen Diabetesgesellschaft (CEDA) und das Do-
nau-Symposium der FID gemeinsam mit der Frühjahrstagung der Schweizerischen Gesellschaft 
für Endokrinologie und Diabetologie in Bern statt. Wenn Sie sich fragen, was denn Bern mit der 
Donau zu tun habe und wieso gerade hier ein Donau-Symposium stattfinden soll, darf ich Sie 
auf http://aarelauf.ch/geologie-2/ (Stichwort „Aare-Donau“) verweisen. Da werden Sie feststellen, 
dass vor Jahrmillionen die Aare, Wahrzeichen unserer Stadt, einer der Hauptzuflüsse der Donau 
war. Die Aare war nämlich im Laufe der geologischen Entwicklung nacheinander der Oberlauf der 
Donau, der Rhone und später des Rheins. Wahrlich eine Zentraleuropäische Region!
Wir haben für Sie ein Programm zusammengestellt, welches einerseits zahlreiche klinisch hoch-
aktuelle Themen beleuchtet und Ihnen andererseits einen Einblick über die diabetologische For-
schung in der Schweiz geben wird. 
Auch touristisch und kulturell hat die Schweizer Hauptstadt einiges zu bieten. „Sie ist die Schöns-
te, die wir je gesehen haben“ schrieb jedenfalls Johann Wolfgang von Goethe in einem Brief an 
seine Freundin Charlotte von Stein, als er sich im Jahre 1779 in Bern aufhielt. Ein Besuch in Bern 
wird auch Ihnen Gelegenheit geben, sich von der homogenen Altstadt (UNESCO-Weltkulturerbe), 
der charakteristischen Aareschlaufe und dem überwältigenden Alpenpanorama verzaubern zu 
lassen.
Mit herzlichen Grüssen, und willkommen in Bern!
 
Prof. Dr. Peter Diem, Tagungspräsident
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7Thursday, June 30, 2016
11:15 – 12:00 FID Board Meeting    (Kursraum 4, U1)
12:30 – 13:30  Lunch-Symposium:  (Auditorium Ettore Rossi)
 Beyond Glucose: From Surrogate Markers to Endpoints – 
 The Impact of Outcome Studies in the Treatment of T2D 
 (sponsored by Boehringer Ingelheim)
 Chair: P. Diem, Bern
 H. Drexel, Feldkirch: Reduction of Mortality in High Risk Patients with   
 Empagliflozin - Implications for Treatment Decisions in T2D
 A. Zanchi, Lausanne: Influence of Kidney Function on Treatment Choices in  
 T2D - a Swiss Example
13:45 – 14:10  Welcome Address (Auditorium Ettore Rossi)
 R. Lehmann, Zurich; P. Diem , Bern
14:10 – 15:30 Opening Session (Auditorium Ettore Rossi)
 Chair: P. Diem, Bern; R. Lehmann, Zurich
14:10 – 14:50 P. Scherrer, Dallas: The Role of the Adipose Tissue in Diabetes and   
 Obesity
14.50 – 15:30 H. Steinke, Bern: Johann Conrad Brunner and his Studies on    
 Pancreatectomy
15:30 – 16:00 Coffee Break (Foyer, Kursraum 1)
16:00 – 17:40 Session 1:  (Auditorium Ettore Rossi)
 Update on Novel Treatment Options in Diabetes and Metabolism
 Chair: E. Christ, Bern; W. Waldhäusl, Vienna
16:00 – 16:25 R. Weitgasser, Salzburg: New Insulins
16:25 – 16:50 M. Nauck, Bochum: GLP1-Analogs
16:50 – 17:15 C. Ehrenbichler, Innsbruck: New Treatment Options for    
 Hypercholesterolemia
17:15 – 17:40 N.C. Schloot, Dusseldorf: Diabetes Disease Classification: Relevance to  
 Pathophysiology and Treatment
17:40 – 18:00  Coffee Break (Foyer, Kursraum 1)
18:00 – 19:00 Satellite-Symposium:  (Auditorium Ettore Rossi)
 Beyond Glucose Lowering: GLP-1Effects on Body Weight and   
 Cardiovascular System
 (Sponsored by Novo-Nordisk)
 Chair: M. Donath, Basel
 Speakers: J.J. Holst, Copenhagen and S. Bilz, St. Gallen
19:30  Welcome Reception (Inselspital, Main Building, Top Floor)
Referenzen:  
1 Del Prato S et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 
4-year data. Diabetes Obes Metab. 2015 Jun;17(6):581-90. 2 Fachinformation FORXIGA®, www.swissmedicinfo.ch. 3 Fachinformation XIGDUO® XR, www.swissmedicinfo.
ch. 4 Bailey CJ, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-
controlled trial. Lancet 2010;375:2223–33. 5 Bailey CJ, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, 
double-blind, placebo controlled 102-week trial. BMC Med 2013;11:43. 6 Weber MA, et al. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-
angiotensin system blockade Blood Press. 2016 Apr;25(2):93-103. 7 Weber MA et al. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with 
type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study Lancet Diabetes Endocrinol. 2016 Mar;4(3):211-20.
8 Henry RR, et al. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial.Int J Clin Pract 2012;66:446-56. 
9 IMS Health Total Patient Tracker, March 2016; IMS Health Longitudinal Patient Databases (Disease Analyzer), March 2016; IMS NPA Market Dynamics Data, April 
2014-December 2015; IMS Health Longitudinal Patient Database (LRx), March 2015. * FORXIGA®  und XIGDUO® XR sind nicht für die Behandlung von Adipositas oder 
Bluthochdruck indiziert. § Blutdrucksenkung in Abhängigkeit vom HbA1c-Ausgangswert.
FORXIGA® Z: Dapagliflozin, Filmtabletten zu 5 mg und 10 mg; Liste B. I: Monotherapie: Diabetes mellitus Typ 2, wenn Diät und körperliche Aktivität 
keine ausreichende glykämische Kontrolle ermöglicht. Add-on-Kombinationstherapie: in Kombination mit oralen Antidiabetika (Metformin, DPP-4-
Hemmern [mit oder ohne Metformin], Sulfonylharnstoff) und/oder Insulin (mit oder ohne Metformin), wenn diese Behandlung zusammen mit Diät 
und körperlicher Aktivität keine ausreichende glykämische Kontrolle ermöglicht. D: Anfangsdosis: 1× täglich 5 mg; bei guter Verträglichkeit und ungenügender glykämischer Kontrolle Erhöhung auf 1× täglich 10 mg. KI: Überempfindlichkeit gegenüber dem 
Wirkstoff oder einem der Hilfsstoffe. V: nicht empfohlen bei: Diabetes mellitus Typ 1 oder diabetischer Ketoazidose, Volumenmangel, Einnahme von Schleifendiuretika oder Pioglitazon, hereditäre Galactose-Intoleranz, Lactase-Mangel oder Glucose-Galactose-
Malabsorption. IA: Dapagliflozin kann den diuretischen Effekt von Diuretika verstärken. UAW: sehr häufig: Hypoglykämie (bei Anwendung mit SU oder Insulin). Häufig: Vulvovaginitis, Balanitis und verwandte Infektionen des Genitalbereichs, Harnwegsinfektionen, 
Volumenmangel, Rückenschmerzen, Polyurie, erhöhter Hämatokrit, Dyslipidämie. Gelegentlich, selten, sehr selten: siehe www.swissmedicinfo.ch. Weitere Informationen: www.swissmedicinfo.ch oder AstraZeneca AG, 6301 Zug, www.astrazeneca.ch. 
XIGDUO® XR Z: Dapagliflozin, Metformin mit retardierter Wirkstofffreisetzung (XR); Filmtabletten zu 5 mg/500 mg, 5 mg/1000 mg, 10 mg/500 mg und 10 mg/1000 mg; Liste B. I: Xigduo XR ist indiziert bei Erwachsenen mit Diabetes mellitus Typ 2, als Ergänzung zu Diät und 
Bewegung zur Verbesserung der Blutzuckerkontrolle; wenn der Blutzucker mit Metformin allein nicht ausreichend kontrolliert wird; wenn bereits mit der Kombination aus Dapagliflozin und Metformin als separate Tabletten behandelt wird; in Kombination mit einem DPP4 Inhibitor 
oder Insulin, wenn unter der Behandlung mit Metformin und einem DPP4 Inhibitor oder mit Metformin und Insulin keine ausreichende glykämische Kontrolle erreicht wird. D: Grundsätzlich 1× tägl. nach laufendem Behandlungsregime sowie nach Wirksamkeit und Verträglichkeit, 
maximal 10 mg/2000 mg. KI: Überempfindlichkeit gegenüber den Wirkstoffen oder einem der Hilfsstoffe; Diabetes mellitus Typ-1; akute oder chronisch metabolische Azidose, inklusive diabetische Ketoazidose; mässige 
bis starke Nierenfunktionsstörung (Kreatinin-Clearance <60 ml/min); Einschränkung der Leberfunktion, Schwangerschaft, Stillzeit. V: Laktatazidose, eingeschränkte Nierenfunktion, Überempfindlichkeitsreaktionen, 
ältere Patienten (≥75 J.), Volumenmangel, Einnahme von Schleifendiuretika oder Pioglitazon. IA: Dapagliflozin: kann den diuretischen Effekt von Diuretika verstärken. Metformin: Glukokortikoide, 
2 Sympathomimetica, Diuretika, Phenothiazine, Schilddrüsenhormone, Östrogene, orale Kontrazeptiva, Hormonersatzpräparate, Phenytoin, Nicotinsäure, Calciumkanalblocker, Isoniazid, Tetracosactid, Furosemid, 
Nifedipin, Alkohol, H2 Antagonisten, Clonidin, Reserpin, Chinolone. UAW: Sehr häufig: Hypoglykämie (bei Anwendung mit Insulin). Häufig: Vulvovaginitis, Balanitis und verwandte Infektionen des Genitalbereichs, 
Harnwegsinfektionen, Polyurie. Gelegentlich, selten, sehr selten: siehe www.swissmedicinfo.ch. Weitere Informationen: www.swissmedicinfo.ch oder AstraZeneca AG, 6301 Zug. www.astrazeneca.ch M
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XIGDUO® XR: Der einzige SGLT2-Hemmer mit Metformin XR3
3-facher Nutzen 
für Ihre Patienten 
von Anfang an:
NEU
Starke und anhaltende 
HbA1c-Senkung1–5,8
Signifikante 
    Gewichtsreduktion1–5,8,*
Signifikante 
Blutdrucksenkung1,6,7,*,§
 1 × tägliche Dosierung3
Für Ihre Patienten mit Typ-2-Diabetes
FORXIGA® und XIGDUO® XR: 
Direkt nach Metformin2,3
 Der erste SGLT2-Hemmer mit 4-Jahres-Langzeitdaten1
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Reductions that motivate in Type 2 diabetes
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Friday, July 01, 2016 (Program Auditorium Ettore Rossi)
08:15 – 09:00 FID Plenary Meeting    (Auditorium Ettore Rossi)
09:00 – 10:15  Session 2:      (Auditorium Ettore Rossi)
 Hot Topics in Diabetes
 (supported by the Swiss Diabetes Foundation)
 Chair: M. Brändle, St. Gallen; T. Temelkova-Kurtschiev, Sofia
09:00 – 09:25 M. Roden, Dusseldorf: Adaptation of Energy Metabolism in NAFLD   
09:25 – 09:50 M. Brändle, St. Gallen: Health Economics of Diabetes for the Beginner
09:50 – 10:15 V. Schwitzgebel, Geneva: Monogenetic Diabetes
 
10:15 – 10:45  Coffee Break (Foyer, Kursraum 1)
10:45 – 12:30 Symposium: (Auditorium Ettore Rossi)
 Technological Solutions to Address Challenges in Diabetes and Obesity
 (sponsored by Medtronic / Covidien)
 Chair: M. Laimer, Bern; P. Kempler, Budapest
 R. Vigersky, Bethesda: What Role for Continuous Glucose Monitoring in T2  
 Diabetes? 
 B. Guerci, Nancy: When Intensive Insulin Therapy Fails in Type 2 Diabetes: The  
 Role of Pump Therapy
 T. Köstler, Schlieren/Basel: Update Bariatric Surgery: Which Conservative and  
 Surgical Methods Are Available?”
 D. Kröll, Bern: Metabolic Surgery – An Update from Surgical Perspective
 Panel Discussion
12:15 – 14:00 Lunch (Foyer, Kursraum 1)
12:30 – 14:00 Poster Session (Auditorium Ettore Rossi)
 Chair: T. Stulnig, Vienna; N. Lalic; Belgrade
14:00 – 15:40 Session 3:  (Auditorium Ettore Rossi)
 The Role of Alpha-Cells in Diabetes
 Chair: J. Philippe, Geneva; M. Roden, Dusseldorf
14:00 – 14:25 B. Thorens, Lausanne: Recognition and Reaction to Hypoglycemia
14:25 – 14:50 F. Knop, Copenhagen: Regulation of Glucagen Secretion from the Alpha-Cells
14:50 – 15:15 Y. Gosmain, Geneva: The Alpha-Cell in Type 1 and Type 2 Diabetes
15:15 – 15:20  Short Break (Foyer, Kursraum 1)
15:20 – 17:30 Session 4:    (Auditorium Ettore Rossi)
 From Islets and Transplantation to the Artificial Pancreas
 Chair: R. Lehmann, Zurich; C. Stettler, Bern
15:20 – 16:00  R. Lehmann, Zurich: Long-Term Follow-Up of Simultaneous Islet-Kidney  
 Transplantation 
16:00 – 16:25 N.S. Kenyon, Miami: Islet Transplantation from the Beginning to the Future
16:25 – 17:05 C. Stettler, Bern: Artificial Pancreas - Role of Exercise and Food
17:05 – 17:30 J. Bolinder, Stockholm: From Pancreas Transplantation to Diabetes   
 Technologies
17:30 – 17:50 Coffee Break (Foyer, Kursraum 1)
17:50 – 18:50  Satellite Symposium:  (Auditorium Ettore Rossi)
 Sugar and the Heart
 (sponsored by Astra Zeneca)
 Speakers: M. Donath, Basel (Endocrinologist) and  
 T. Burkhard, Basel (Cardiologist)
20:00 Dinner (Restaurant Gurten; Pavillon)
10:45 – 12:05 Parallel Session:  (Langhans Auditorium)
 Diabetes un Endocrine Disease
 supported by the Swiss Society of Endocrinology and Diabetes
 Chair: E. Christ, Bern; F. Pralong, Lausanne
10:45 – 11:05 C. Meier, Basel: Diabetes & Osteoporosis
11:05 – 11:25 C. Henzen, Lucerne: Diabetes & Hyperparathyroidism
11:25 – 11:45 S. Bilz, St. Gallen: Diabetes & Growth Hormone
11:45 – 12:05 P. Wiesli, Frauenfeld: Diabetes & Cortisone
13:30 – 15:40  Parallel Session: (Langhans Auditorium)
 Diabetes-Update für Berater/-innen (in German)
13:30 – 14:00 E. Horat, Bern: Lösungsorientiert Kommunizieren
14:00 – 14:30 R. Fricker, Bern: verschiedene Fazetten der Kohlenhydrate
14:30 – 15: 00 L. Bally, Bern: Continuous Glucose Monitoring zur Therapieentscheidung
15:00 – 15:30 B. Chappuis, Burgdorf: Neue Diabetesmedikamente - Wird nun Alles Besser?
Friday, July 01, 2016 (Parallel Sessions)
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Saturday, July 02, 2016
08:15 – 09:30 Session 5:    (Auditorium Ettore Rossi)
 Oral Presentations
 Chair: E. Hatziagelaki, Athens; E. Standl, Munich
08:15 Dehais et al.: GoCARB: A Computer Vision-Based Smartphone System  for  
 Carbohydrate Counting
08:30 Dietrich et al.: Impaired Glucose Tolerance in Mice with β-Cell-Specific  
 Deletion of  PKBα
08:45 Hohendorff et al.: Response to SGLT-2 Inhibitor May Be Altered in HNF1A- 
 MODY.
09:00  Holl et al.: Differential Use of Insulin Pumps in Patients with Type-1-Diabetes of  
 Different Age-Groups: Analysis of the DPV (Diabetes Prospective Folllow-Up)  
 Initiative
09:15 Pesta et al.: Type II Musclefibers Have an Increased Potential for Reactive  
 Oxygen Production
09:30 – 10:30 Session 6: (Auditorium Ettore Rossi)
 From Obesity to Type-2 Diabetes
 Chair: Z. Stanga, Bern; C. Herder, Dusseldorf
09:30 – 09:50 A. Golay, Geneva: The Double Insulin Resistance
09:50 – 10:10 M. Donath, Basel: Targeting Inflammation in Obesity to Prevent and Treat  
 Type 2 Diabetes
10:10 – 10:30 P. Gerber, Zurich: Fructose: Guilty or Innocent?
10:30 – 11:00  Coffee Break    (Foyer, Kursraum 1)
11:00 – 12:20 Session 7:  (Auditorium Ettore Rossi)
 Update on Pathophysiology of Diabetes
 Chair: G. Spinas, Zurich; H. Schatz, Bochum
11:00 – 11:20 N.C. Schloot, Dusseldorf: Autoimmunity in Human Type 1 Diabetes
11:20 – 11:40 P. Maechler, Geneva: Mitochondrial Function and Insulin Secretion
11:40 – 12:00 K. Ahmed, Zurich: MircoRNA and Islet Function
12:00 – 12:20 J. Krützfeldt, Zurich: MicroRNA and Insulin Resistance
12:20 – 12:40  Closing Session (Auditorium Ettore Rossi)
 Including Presentation of the Next Congress Venue
12:40 Farewell Apero (Foyer, Kursraum1)
Beyond glucose lowering:
After several years in use, GLP-1 has proven to be an 
effective therapy in treating patients with type 2 diabetes.
Join the Novo Nordisk sponsored symposium during 
the Donau Symposium on Thursday 30th of June to find 
out more about the versatility of GLP-1 therapies.
RICHARD HARTMAN
NETHERLANDS
Richard has type 2 diabetesWe look forward to seeing you in Bern!
GLP-1 effects on 
body weight and 
cardiovascular 
system
Chair: M. Donath, University Hospital Basel
Speakers: J.J. Holst, University of Copenhagen 
Professor Holst has pioneered the isolation and 
characterization of GLP-1 and discovery of the 
potential of GLP-1 for treatment of diabetes. He 
will present the pleiotropic effects of GLP-1
 S. Bilz, Kantonsspital St. Gallen 
Dr. Bilz will point out the clinical relevance of 
GLP-1 based therapies
Date: Thursday, June 30, 2016
Time: 18:00–19:00 followed by an Apéro
Location: Inselspital Bern, Auditorium Rossi
 No registration needed
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Title:
GoCARB: A Computer Vision-Based Smartphone System for Carbohydrate Counting
Authors / Address of institution:
Joachim Dehais1, Marios Anthimopoulos1, Sergey Shevchik1, Ransford Botwey1, Daniel Rhyner1,2, 
Lia Bally2, Pieter Diem2, Christoph Stettler2, Stavroula Mougiakakou1,2
1 ARTORG Center for Biomedical Engineering Research, University of Bern. Switzerland
2 Department of Endocrinology, Diabetes and Clinical Nutrition, Bern University Hospital 
“Inselspital”, Switzerland
Background / Introduction:
Estimating a meal's carbohydrate (CHO) counting is of importance in diabetes self-management. 
However, it remains a challenging task in daily life. GoCARB is a computer vision-based 
smartphone application designed to estimate meal’s CHO content h with an error less than ±20 
grams/meal and minimum user interaction.
Methods:
The GoCARB prototype was developed based on the assumptions that the plate is circular 
and shallow and the food items in the plate are not occluded. In a typical scenario, the user 
places a reference object (e.g. credit card) next to the plate and acquires two images using a 
smartphone's camera. Then, the different food items on the plate are segmented and recognized 
while their 3D shape is reconstructed. Based on the shape, the segmentation results and the 
reference object, the volume of each item is estimated. Finally, the CHO content is calculated by 
combining the food type with its volume, and using nutritional databases. GoCARB’s validation 
involved a three-step procedure: i) testing in a laboratory setup with 24 dishes, ii) ple-clinical 
study involving 19 adults with T1D, and iii) randomized, prospective, single-center, two-
period, with cross-over after one week clinical trial involving 20 adults with T1D under sensor-
augmented pump therapy.
Results:
In the laboratory setup, GoCARB was able to estimate the CHO content of 24 meals with a mean 
absolute error of 6±8 CHO grams. In the preclinical study, each participant was asked to count 
the CHO content of each meal. Then, he/she was asked to estimate the CHO content by using 
GoCARB. A total of 114 estimates on 60 meals were used. The mean absolute error was 27.89 
± 38.20 CHO grams of CHO for individuals with T1D and 12.28 ± 9.56 CHO grams by using the 
GoCARB system. Participants also strongly supported using the software for daily counting. 
During the clinical trial, the participant’s glucose levels, insulin intake, energy expenditure, 
and eating habits were gathered. These data were then processed to calculate useful diabetes 
management measures and the effect of GoCARB on them. An early analysis showed a positive 
influence for the use of GoCARB: the average and standard deviation of glucose level were lower, 
and so was the average increase in postprandial glucose.
Conclusion:
According to the three-step validation procedure the GoCARB system the CHO content errors 
below 20 grams and is significantly more accurate than the average individual with T1D. 
Furthermore, it seems that its usage positively impacts the glucose profile.
Abstracts 
Oral Presentation
Title:
Impaired glucose tolerance in mice with ß-cell-specific deletion of PKBα
Authors / Address of institution:
M.G. Dietrich1,2; R.A. Zuellig1; F.C. Lucchini 3; S. Wueest 3; M. Niessen1,2; D. Konrad 3; G.A. Spinas1,2;  
O. Tschopp1,2
1 Division of Endocrinology, Diabetes & Clinical Nutrition, University Hospital Zurich, Switzerland
2 Competence Center Personalized Medicine UZH/ETH, Zurich, Switzerland
3 Division of Pediatric Endocrinology and Diabetology, University Children's Hospital Zurich, 
Switzerland
Background / Introduction:
Protein kinase B (PKB)/Akt is considered a key target downstream of insulin receptor substrate 2 
(IRS2) in the regulation of pancreatic β-cell mass. There exist three isoforms of PKB, i.e. PKBα/Akt1, 
PKBβ/Akt2, and PKBγ/Akt3, which are all expressed in pancreatic β-cells. It is, however unclear, 
whether these isoforms exert differential effects with regard to functional β-cell mass. The aim of 
this study was to investigate in mice the effect of β-cell specific deletion of PKBα (βpkbαKO) on 
glucose homeostasis, β-cell function and β-cell mass.
Methods:
Mice were rendered insulin resistant by feeding a high-fat diet (HFD) and characterized 
metabolically by intraperitoneal glucose (ipGTT), insulin tolerance tests and hyperglycemic 
clamps. In addition, glucose-stimulated insulin secretion (GSIS) was assessed in isolated islets and 
islet morphology was studied in pancreatic tissue sections.
Results:
Western blot analysis showed that PKBα was normally expressed in control mice, but absent in 
β-cells from βpkbαKO mice. Under normal chow diet male βpkbαKO mice exhibited reduced 
glucose tolerance with significantly increased AUC (+22.6% ± 6.5%; p ≤ 0.05) in adult live, i.e. at 
the age of 26 weeks. HFD accelerated the onset of impaired glucose tolerance with significantly 
increased AUC (+10.06% ± 3.6%; p ≤ 0.05) already at age of 12 weeks (6 weeks on HFD). Plasma 
insulin levels during GTT and hyperglycemic clamps were reduced in HFD-fed βpkbαKO mice. 
However, GSIS was increased in islets from chow fed but decreased in islets from HFD-fed 
βpkbαKO mice. Preliminary analyses of pancreas morphology from 28 weeks old mice revealed 
a 50% decrease of β-cell area in βpkbαKO mice under chow and HFD as compared to control 
littermates.
Conclusion:
Thus, this study shows for the first time that β-cell specific loss of PKBα results in impaired 
glucose tolerance, potentially due to reduced β-cell mass. Whether the reduced β-cell mass in 
adulthood is the result of islet loss or of failure to form new islets, or even caused by impaired 
embryonic development is currently under investigation.
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Title:
Response to SGLT-2 inhibitor may be altered in HNF1A-MODY.
Authors / Address of institution:
Hohendorff J, Szopa M, Skupien J, Klupa T, Malecki MT
Background / Introduction:
MODY accounts for 1-5 % of all diabetes cases and most of them are HNF1A- and GCK-MODY. 
Dietary intervention is generally sufficient to maintain good glycemic control in subjects with 
GCK gene mutation. HNF1A gene mutations affect insulin secretion to a greater extent. For 
patients with genetically confirmed HNF1A-MODY sulfonylurea therapy should be considered as 
the first-line treatment. It was shown that HNF1A controls SGLT2 (sodium-glucose co-transporter 
2) expression which results in increased glycosuria in HNF1A-MODY patients. Therefore, response 
to SGLT2 inhibitors in HNF1A-MODY patients may be altered. In this pilot study, we aimed to 
assess differences in response to a single morning application of 10 mg dapagliflozin in HNF1A- 
and GCK-MODY patients.
Methods:
A total of 21 patients were included in the study: 11 with GCK-MODY and 10 with HNF1A-MODY. 
Dapagliflozin was added to patients current treatment regimens - all GCK-MODY subjects 
were on diet only, whereas HNF1A-MODY patients were on diet (1), SU (6), SU combined with 
metformin (2) and SU combined with 3U/d of insulin (1). Fasting plasma glucose (FPG), urine 
glucose concentration and urinary glucose-to-creatinine ratio (GCR) were measured in the 
morning of the administration day and the day after. Additionally, patients were asked to 
perform self-monitoring of blood glucose twice – on the administration day and the day before.
Results:
There were no differences in mean HbA1c (6,25; 6,06%) nor BMI (23,1; 24,6 kg/m^2) between 
the groups. GCK-MODY patients had higher mean FPG (6,81 vs. 5,66 mmol/l, p=0,0137). Mean 
reduction in FPG after dapagliflozin administration was 0,63 in GCK-MODY, whereas in HNF1A-
MODY patients was 0,24 mmol/l (p=0,2367). This could suggest altered response to SGLT2 
inhibitors in HNF1A-MODY due to impaired SGLT2 function. Moreover, we found a difference in 
median increment in GCR after SGLT2 inhibitor administration between GCK-MODY and HNF1A-
MODY patients (24,5 vs.14,0 p=0,0447).
Conclusion:
To summarize, SGLT2 inhibitors seems to be less efficient in HNF1A-MODY than in GCK-MODY. 
This finding requires further studies.
Financial support: The study was supported by an EFSD New Horizons Programme award.
Title:
Differential use of Insulin Pumps in Patients with Type-1-diabetes of different Age-groups: 
Analysis of the DPV (Diabetes Prospective Follow-up) initiative with centers from Germany, 
Austria, Luxemburg and Switzerland
Authors / Address of institution:
Holl, Reinhard W; Bohn, Barbara (Ulm), Heidtmann Bettina (Hamburg), Hofer Sabine E (Innsbruck), 
Rosenbauer Joachim (Düsseldorf ), Lilienthal Eggert (Bochum), Witsch Michael (Luxemburg), 
Zlamal-Fortunat, Sandra(Klagenfurt), Laimer, Markus (Bern)
Contact: Reinhard W. Holl, University of Ulm, Institute for Epidemiology and Medical Biometry, 
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Background / Introduction:
Data on therapy options in real-life patient care are important to monitor trends in diabetes 
therapy as well as adherence to current guidelines together with short-term and long-term 
outcome. Increasing use of diabetes technology, including insulin pumps and continuous 
glucose monitoring, is one of the most dynamic trends in type-1 diabetes management during 
recent years. We investigated age-differences in the use of insulin pumps since the year 2000.
Methods:
The DPV registry is one of the largest ressources available on care and outcome of diabetes 
in Germany and Austria, including both pediatric and adult patients. Recently centers from 
Luxemburg (pediatrics) and Switzerland (internal medicine). In total, the registry includes 3.7 
Million patient visits from 454,645 patients with diabetes. This abstract focusses on type-1-
diabetes, with 2,167,530 visits from 108,052 patients. Use of insulin pumps was evaluated by year 
of treatment and age-group. A total of 445 specialized diabetes centers contributed data (258 
pediatric, 187 internal medicine). SAS 9.4 was used for data analysis.
Results:
In total, 31,188 patients with type-1 diabetes using insulin pumps are included in the DPV 
registry. In adult patients (age > 18 years), pump use increase fom 24.1 % in the year 2000 to 36.2 
% in 2015. In adolescents (12-18 years), was even more pronounced (2000: 5.8 %, 2015: 41.6 %). 
School-age patients (6-12 years) displayed an increase from 1.1 % of pump use in 2000 up to 53.9 
% in 2015. The most striking pattern was observed in pre-school children ( < 6 years of age): 0.8 % 
used insulin pumps in 2000, increasing up to 83.1 % in 2015.
Conclusion:
The use of CSII increased in all age-groups, however there was a clear age difference with later 
adoption of insulin pumps, but more rapid increase in this therapy for younger children. Today, 
the vast majority of toddlers uses insulin pumps. Population-based registries documenting the 
process and outcome of diabetes care, are a valuable tool to monitor longitudinal trends in real-
life patient care.
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Background / Introduction:
Increased reactive oxygen species (ROS) production in skeletal muscle has been associated with 
the development of insulin resistance and type 2 diabetes (T2D). Preliminary evidence suggests 
that fast-twitch type II fibers may possess a higher potential for ROS production than slow-twitch 
type I fibers. First-degree relatives of patients with T2D have ~30% increased number of type 
II muscle fibers. Therefore, the connection between oxidative stress, impaired mitochondrial 
function, and insulin resistance warrants further investigation.
Methods:
Site-specific ROS production of three main sites (CIQ, CIIF, CIIIQo) was assessed by superoxide 
Amplex Red fluorescence assay in two muscles with a different fiber spectrum from slow to 
fast (soleus, white gastrocnemius) in wildtype mice (C57BL/6J). Mitochondrial content was 
determined by citrate synthase activity (CSA).
Results:
We find that ROS production per wet weight is higher in soleus than in white gastrocnemius 
at CIQ with a trend at CIIF and no difference at CIIIQo. When ROS production is normalized for 
mitochondrial content, ROS production at CIQ is 50% higher in white gastrocnemius than in 
soleus with a similar strong trend at CIIIQo and no difference at CIIF.
Conclusion:
Our results suggest intrinsic differences in the potential for ROS production between fast- and 
slow-twitch muscle fibers which are independent of mitochondrial content.
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Background / Introduction: 
Type 2 diabetes (T2DM) is an epidemic disease in Asia, with a younger age and lower BMI at diagnosis in Asians vs non-Asians. 
Methods: 
This patient-level analysis compared outcomes in Asians and non-Asians with T2DM from 16 RCTs (target FPG ≤ 100 mg/dL, ≥ 24-
week duration) adding Gla-100 to OADs. Data from Asians and non-Asians were compared overall and by concomitant metformin 
(MET) plus sulphonylurea (SU) therapy at baseline and Week 24.
Results: 
Of 3,586 study participants, 235 were Asian. Among OADs, MET+SU was the most common co-treatment with Gla-100. Outcomes 
at Week 24 for overall and MET+SU subgroups are shown in the Table. Asians were younger, had a lower BMI and FPG, but 
similar baseline HbA1c vs non-Asians. Asians had a statistically significant higher adjusted mean HbA1c at week 24 and were less 
likely to achieve target HbA1c <7.0%, but more Asians had FPG ≤100 mg/dL compared with non-Asians. Final Gla-100 doses and 
hypoglycemia event rates were similar in Asians and non-Asians. Lower weight gain was observed in Asians (P = 0.01). The results 
of the MET+SU subgroup reflected those of the overall population.
Conclusion: 
This post-hoc analysis suggests that at similar Gla-100 doses and hypoglycemia frequency, HbA1c control in Asian T2DM patients 
appears poorer compared with non-Asian patients, despite better FPG control. More studies are needed to explore potential 
differences in treatment responses between Asian and non-Asian T2DM patients.
Table. Clinical Outcomes in Asian and non-Asian People With T2D Initiating Gla-100 Therapy
Gla-100 Overall Gla-100 + MET + SU
Parameter (SD) Asian
(n = 235)
Non-Asian
(n = 3,351)
P Value Asian
(n = 111)
Non-Asian
(n = 1,513)
P Value
Baseline
Age, years 53.7 (9.0) 57.9 (9.7) < 0.001 54.1 (8.8) 58.5 (9.1) < 0.001
Diabetes duration, years 8.9 (6.0) 8.9 (6.2) 0.92 9.6 (4.8) 9.4 (6.3) 0.74
Weight, kg 70.4 (12.6) 87.3 (18.1) < 0.001 70.1 (13.2) 88.6 (17.0) < 0.001
BMI, kg/m2 27.1 (3.9) 30.8 (5.3) < 0.001 27.3 (4.3) 31.2 (4.9) < 0.001
HbA1c, % 8.6 (1.0) 8.7 (1.1) 0.08 8.4 (0.9) 8.6 (1.0) 0.04
FPG, mg/dL 169 (46) 194 (55) < 0.001 160 (38) 189 (52) < 0.001
Insulin dose, U/kg 0.18 (0.04) 0.16 (0.08) < 0.001 0.17 (0.04) 0.14 (0.05) < 0.001
Week 24 endpoints:
Adjusted HbA1c, % 7.42 (0.06) 7.16 (0.02) < 0.001 7.16 (0.08) 7.07 (0.02) 0.27
Adjusted HbA1c change from baseline −1.30 (0.06) −1.55 (0.02) < 0.001 −1.41 (0.08) −1.50 (0.02) 0.27
HbA1c ≤ 7.0 %, n (%) 90 (41.9) 1605 (50.7) < 0.001 44 (43.1) 783 (53.8) 0.14
Adjusted FPG change from baseline, mg/dL −78.1 (2.6) −75.2 (0.7) 0.27 −74.4 (3.7) −68.3 (0.9) 0.11
FPG ≤ 100 mg/dL, n (%) 101 (47.6) 1076 (34.0) 0.21 44 (44.9) 468 (32.5) 0.37
Adjusted hypoglycemiaa, events per patient-year 4.3 (0.6) 5.5 (0.2) 0.09 6.5 (1.1) 7.4 (0.3) 0.45
Adjusted weight change from baseline, kg 1.3 (0.2) 1.9 (0.1) 0.01 1.4 (0.3) 1.8 (0.1) 0.25
Adjusted insulin dose, U/kg 0.47 (0.02) 0.45 (0.00) 0.16 0.36 (0.02) 0.41 (0.01) 0.045
Data presented represent mean (SD) for baseline and adjusted mean (SE) for Week 24 endpoint, except for items n (%).
aOverall hypoglycemia defined as PG <70 mg/dL or third-party assistance required.
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Background / Introduction: Hypoglycemia during insulin initiation and intensification can be a barrier to dose optimization and 
achievement of glycemic control targets. 
 
Methods: This post-hoc subject-level analysis examined standardized data from 16 RCTs (FPG target ≤ 100 mg/dL, ≥ 24 weeks 
duration) adding Gla-100 to OADs in insulin-naive people with T2D. The impact was studied of overall hypoglycemia frequency 
(confirmed PG < 70 mg/dL or assistance required, stratified according to 0, 1−3, 4−6, or > 6 events during titration from Weeks 
0−8) on glycemic outcomes and insulin dose at Week 24. 
 
Results: Data from 3,549 participants were analyzed. Group size declined as hypoglycemia frequency increased but mean age 
was similar (58 years) across all groups. Those with > 4 hypoglycemic events during titration had the lowest baseline body weight, 
FPG, and HbA1c, and longer diabetes duration (Table). In contrast, those experiencing less hypoglycemia (≤ 3 events) had higher 
BMI, FPG and HbA1c at onset with a greater change in insulin dose from baseline to Week 24.  
Conclusion:  Lower hypoglycemia incidence occurs during insulin titration in people with T2D with a greater insulin resistance 
(higher insulin dose requirement and smaller HbA1c reduction), in contrast to people experiencing more hypoglycemia during 
titration with greater HbA1c reduction.  
 
Table. Patient Characteristics Stratified by Frequency of Hypoglycemic Events During Gla-100 Titration 
 Frequency of Hypoglycemic Events During Titration (Week 0–8) 
Parameter 0  n = 2,573 
1–3  
n = 732 
4–6 
n = 152 
> 6 
n = 92 
Duration of diabetes, years  8.6 (6.0) 9.5 (6.4) 10.2 (6.5) 9.9 (7.4) 
Baseline body weight, kg 87.7 (18.5) 83.3 (17.4) 77.4 (14.6) 77.8 (15.1) 
Baseline BMI, kg/m2  31.0 (5.3) 29.6 (4.9) 28.3 (4.5) 28.4 (4.5) 
Baseline FPG, mg/dL 194 (54) 187 (52) 186 (64) 184 (55) 
Baseline HbA1c, %  8.8 (1.1) 8.6 (1.0) 8.5 (1.0) 8.5 (0.9) 
Baseline insulin dose, U/kg 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 
Week 24 HbA1c, %* 7.2 (1.04) 7.0 (0.95) 7.1 (0.87) 7.0 (0.91) 
HbA1c change from BL to week 24, %* −1.5 (1.2)  −1.5 (1.1) −1.4 (1.0) −1.5 (1.0) 
Insulin dose change from BL to week 24, U/kg† 0.31 (0.26) 0.20 (0.19) 0.12 (0.16) 0.07 (0.14) 
*0: n = 2,486; 1–3: n = 718; 4–6: n = 152; > 6: n = 91. 
†0: n = 2,573; 1–3: n = 732; 4–6: n = 152; >6: n = 92. 
Data presented represent mean (SD). SD, standard deviation; BL, baseline 
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Background / Introduction: Dyslipidemia is a major risk factor for cardiovascular disease (CVD), being the major cause of
mortality in T2DM.
Methods: This post-hoc patient-level analysis included data from 11 RCTs (target FPG ≤100 mg/dL, ≥24 week duration) 
conducted with insulin glargine 100 units/ml (Gla-100) vs comparator antihyperglycemic drugs from 1999 to 2008. The effects of 
pooled glucose lowering therapy (GLT) on lipid status at baseline and 24 weeks were examined in patients with diagnosed CVD 
at BL and receiving lipid lowering therapy (LLT) at discretion of physicians, patients with CVD not receiving LLT and control
people without CVD, not receiving LLT.
Results: Only 41% (n=1,940) of all T2DM study participants ± CVD (n=4,768) were treated with LLT despite being considered 
at high CV risk and 2,828 did not receive LLT. LLT included statins (88%), fibrates (11%), and others (10%). 97% (with LLT) and
63% (without LLT) had CVD at study entry with LDL-C, non HDL-C, triglycerides (TG) levels above lipid targets 
recommendations at baseline and week 24, whatever LLT (Table). After 24 weeks of GLT, non–HDL-C and TG slightly 
improved; LDL-C, HDL-C levels remained almost unchanged, irrespective of LLT use. Importantly, only 51% of those with T2DM
and CVD received LLT as recommended (AHA/ADA 2015).
Conclusion: Our data suggest modest improvement on non-HDL-C, TG levels with GLT in T2DM study participants with CVD 
and the need to treat people with T2DM optimally with LLT according to current recommendations.
 
Lipid-lowering therapy during trial No lipid-lowering therapy during trial
Diagnosed with CVD at baseline                                     
(n = 1,885)
Diagnosed with CVD at baseline
(n = 1,787)
Without CVD diagnosis at baseline                                         
(n =1,041)
Glucose lowering 
treatment
Gla-100: 51%  other insulins: 16%
NPH: 14%  OADs: 19%
Gla-100: 53%  other insulins: 10%
NPH: 17%  OADs: 20%
Gla-100: 54%  other insulins: 7%
NPH: 24%   OADs: 15%
Baseline Change from baseline to week 24 Baseline
Change from 
baseline to week 24 Baseline
Change from 
baseline to week 24
HbA1c, % 8.7 (1.02) -1.4 (1.13) 8.8 (1.05) -1.5 (1.19) 9.0 (1.09) -1.6 (1.24)
Non-HDL-C, mg/dL 142.85 (48.42) -9.10 (39.67) 159.78 (41.92) -5.20 (29.57) 151.04 (50.31) -3.85 (43.34)
LDL-C, mg/dL 99.94 (37.05) -0.98 (30.48) 120.83 (36.39) 1.51 (27.42) 116.31 (32.96) 0.51 (25.96)
HDL-C, mg/dL 43.83 (11.42) 0.32 (7.17) 45.69 (13.30) 0.56 (10.12) 45.27 (13.08) 0.36 (10.58)
Triglycerides, mg/dL 241.40 (247.69) -51.20 (220.81) 210.99 (163.16) -38.84 (141.93) 181.51 (129.15) -25.83 (106.05)
C-Peptide (nmol/L) 1.19 (0.60) 1.15 (0.59) 1.00 (0.60)
Data represent mean (SD); HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.   P < 0.05 between patients treated with 
lipid lowering therapy vs not treated for HbA1c and all lipid parameters at baseline and change to week 24, except for triglycerides which was significant (P <
0.05) at baseline only.
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Background / Introduction:
Cardiovascular autonomic neuropathy is a common but underestimated diabetes-related 
disorder. Associations between cardiovascular autonomic dysfunction and subclinical 
inflammation, both risk factors of diabetic comorbidities and mortality, have been proposed in 
non-diabetic populations, while data for type 1 and type 2 diabetes are conflicting. Our aim was 
to investigate associations between inflammation-related biomarkers and cardiac autonomic 
dysfunction in rencently diagnosed diabetes patients.
Methods:
We characterised the associations between seven biomarkers of subclinical inflammation 
and cardiac autonomic dysfunction based on heart rate variability (HRV) and cardiovascular 
autonomic reflex tests (CARTs) in 161 individuals with type 1 and 352 individuals with type 
2 diabetes (time since diagnosis of diabetes <1 year). Analyses were adjusted for age, sex, 
anthropometric, metabolic and lifestyle factors, medication and cardiovascular comorbidities.
Results:
In individuals with type 2 diabetes, higher serum interleukin (IL)-18 was associated with lower 
vagal activity (P≤0.015 for association with CARTs), whereas higher levels of total and high-
molecular-weight adiponectin showed associations with very-low-frequency power, an indicator 
of reduced sympathetic activity (P≤0.014). Higher levels of soluble intercellular adhesion 
molecule-1 were associated with indicators of both lower vagal (P=0.025) and sympathetic 
(P=0.008) tone, soluble E-selectin with one indicator of lower vagal activity (P=0.047). Serum 
C-reactive protein and IL-6 were also related to cardiac autonomic dysfunction, but these 
associations were explained by confounding factors. No consistent associations were found in 
individuals with type 1 diabetes.
Conclusion:
Biomarkers of inflammation were differentially associated with diminished cardiac autonomic 
dysfunction as early as in recent-onset type 2 but not type 1 diabetes.
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Background / Introduction: Hypoglycemia during insulin initiation and intensification can be a barrier to dose optimization and 
achievement of glycemic control targets. 
 
Methods: This post-hoc subject-level analysis examined standardized data from 16 RCTs (FPG target ≤ 100 mg/dL, ≥ 24 weeks 
duration) adding Gla-100 to OADs in people with T2D. The impact of metformin (MET), sulfonylurea (SU), or MET + SU on overall 
hypoglycemia frequency (confirmed PG < 70 mg/dL or assistance required) stratified according to 0, 1−3, 4−6, or > 6 events during 
insulin dose titration from Weeks 0−8 was assessed; efficacy and insulin dose change at Week 24 were also examined. 
 
Results: Data from 3,153 people receiving either MET (n = 623), SU (n = 906), or MET + SU (n = 1,624) in combination with Gla-
100 for 24 weeks were analyzed. The concomitant OAD to which Gla-100 is added has a differential effect on HbA1c reduction. 
MET-treated subjects had the shortest diabetes duration and highest baseline BMI; the longest diabetes duration and lowest BMI 
were seen in the SU-only treated group (Table). In all OAD subgroups the majority experienced ≤ 3 hypoglycemic events during 
titration. The frequency of hypoglycemia was inversely related to the baseline BMI in all but the MET + SU-treated group with > 6 
events. The adjusted insulin dose change from baseline was lowest in those with more hypoglycemic events, irrespective of OAD 
treatment. 
Conclusion:  In people with T2D, OADs co-administered with basal insulin therapy influence efficacy outcomes and overall 
hypoglycemia risk during the early period of insulin dose titration. 
 
Table: Patient Characteristics Stratified by Frequency of Hypoglycemic Events and Concomitant OAD During Gla-100 Titration 
Parameter 
Glargine 
+ OAD 
subgroup 
Frequency of Hypoglycemic Events (PG < 70 mg/dL) During Titration 
(Week 0–8) 
0 1−3 4−6 > 6 
Number of people, N (%) 
MET 
MET + SU 
SU 
535 (85.9) 
1047 (64.5) 
683 (75.4) 
75 (12.0) 
421 (25.9) 
168 (18.5) 
6 (1.0) 
100 (6.2) 
35 (3.9) 
7 (1.1) 
56 (3.4) 
20 (2.2) 
Duration of diabetes, years 
MET 
MET + SU 
SU 
6.9 (5.3) 
9.2 (6.0) 
9.5 (6.6) 
9.1 (6.9) 
9.8 (6.3) 
9.6 (6.8)  
11.4 (8.8) 
10.0 (6.4) 
10.2 ( 6.6) 
11.5 (6.9) 
10.6 (8.4) 
8.0 (5.2) 
Baseline BMI, kg/m2 
MET 
MET + SU 
SU 
31.8 ( 5.7) 
31.4 (5.0) 
29.6 (5.2) 
29.3 (4.9) 
30.4 (4.8) 
27.7 (4.6) 
27.6 (5.0) 
28.7 (4.4) 
27.0 (3.9) 
26.0 (4.4) 
29.7 (4.5) 
25.9 (4.1) 
Baseline FPG, mg/dL 
MET 
MET + SU 
SU 
187 (54) 
192 (52) 
202 (57) 
177 (53) 
180 (48) 
206 (58) 
152 (28) 
176 (63) 
222 (66) 
178 (49) 
163 (41) 
242 (59) 
Baseline HbA1c, % 
MET 
MET + SU 
SU 
8.7 (1.1) 
8.7 (1.0) 
9.0 (1.1) 
8.4 (1.0) 
8.4 (0.9) 
8.9 (1.0) 
8.5 (0.8)  
8.4 (0.9)  
9.1 (1.1)  
9.0 (1.0) 
8.2 (0.8) 
9.3 (0.7) 
HbA1c change from baseline to 
Week 24, %  
MET 
MET + SU 
SU 
−1.7 (1.2) 
−1.5 (1.1) 
−1.4 (1.2) 
−1.6 (1.3) 
−1.5 (1.0) 
−1.5 ( 1.3) 
−1.1 (1.0)  
−1.4 (1.0)  
−1.6 (1.2) 
−1.4 (1.5) 
−1.4 (0.8) 
−2.1 (1.1) 
Insulin dose change from baseline 
to Week 24, U/kg 
MET 
MET + SU 
SU 
0.37 (0.28) 
0.31 (0.26) 
0.26 (0.22) 
0.20 (0.19) 
0.20 (0.19) 
0.16 (0.19) 
0.08 (0.06)  
0.16 (0.15)  
0.02 (0.15)   
0.07 (0.09) 
0.08 (0.13) 
-0.01 (0.17) 
Data presented represent mean (SD) unless otherwise specified. SD, standard deviation. SE, standard error. 
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Background / Introduction:
The use of personalized, data-driven models for the real-time prediction of glucose profile 
in individuals with type 1 diabetes (T1D) under sensor-augmented pump (SAP) therapy is of 
imminence importance for diabetes self-management. Scope of the present research is to 
investigate how to tackle issues related to the accuracy of the glucose predictions and time-lags 
(TL) between predicted and measured signals especially in higher prediction horizons (PHs).
Methods:
Sensor glucose (G), insulin pump (I), food intake (CHO), and physical activity (PA) data from six 
individuals with T1D under SAP were used (age: 22-29 years; HbA1c: 6.83 ± 0.75%; body mass 
index: 24.79 ± 4.71 kg/m2). The data provided input to a computational framework composed 
by two layers: Prediction and correction. The prediction layer involves two data-driven models 
(corrected ARX model - cARX; Recurrent Neural Network trained by Unscented Kalman filter 
- uRNN). All models are online adaptive and can be personalized to each individual with T1D. 
The outputs of all models are corrected by an extreme learning machine (ELM) constituting the 
correction layer. The different models were evaluated on the basis of root mean square error 
(RMSE) and TL between predicted and real signals for PH=15, 30 and 45 minutes.
Results:
The results indicate that the use of lifestyle information (CHO and PA) along with data from 
the SAP therapy improves the glucose predictions especially in terms of TL and in the case 
of increased PH. Furthermore, ELM independently of the used model, positively impacts the 
prediction accuracy and reduces the TL for all the PHs. Finally, the cARX model fed with lifestyle 
and SAP data, along with an ELM, achieved lower TL over all the examined models and for all PHs 
with mean RMSE values of 9.4 (1.52) mg/dL and mean TL of 4.2 (2.04) min for PH=15 min, 19.2 
(5.02) mg/dL and 10 (3.16) min for PH=30 min and 23.4 (5.20) mg/dL and 9.2 (5.85) min for PH=45 
min.
Conclusion:
The finding of the presented work need to be confirmed in a larger dataset. The best performing 
setup will be integrated to a system for alarm generation whenever a hypoglycemic event is 
predicted. 
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Background / Introduction:
Observational studies have shown that type 2 diabetes (T2D) is associated with reduced 
pulmonary function. Moreover, interventional studies have shown that exercise can improve 
lung function in patients with T2D. The present study tests the hypothesis that low-volume high-
intensity interval training (HIIT), as an effective and time-efficient alternative to conventional 
exercise programs, improves physical capacity and pulmonary performance in T2D.
Methods:
Twelve sedentary male volunteers with T2D (age: 57±5 years, body mass index (BMI): 31.6±2.2 
kg*m-2, known diabetes duration: 6±2 years, HbA1c: 55.0±10.5 mmol*mol-1) and 5 sedentary 
male glucose-tolerant controls (CON) (age: 55±2 years, BMI: 30.7±2.3 kg*m-2, HbA1c: 36.0±2.4 
mmol*mol-1) underwent a 12-week HIIT using bicycle ergometers with a subsequent 4-weeks 
detraining period. Both groups did not differ in age, sex and BMI. Physical capacity was assessed 
from oxygen consumption at maximum (VO2max), peak oxygen pulse (CO) and maximum 
performance (Wattmax). Lung function was assessed by determining forced vital capacity 
(FVC), forced expiratory volume in one second (FEV1), maximum ventilation (VE) and breathing 
frequency (BF).
Results:
Compared to CON, patients with T2D showed no difference in parameters of physical capacity 
(e.g. VO2max or Wattmax) and lung function (e.g. FEV1 or FVC) at baseline, except for a reduced 
VE (P<0.05). After 12 weeks of HIIT, patients with T2D increased their lung function (FVC 
(+0.47±0.36 l), FEV1 (+0.27±0.19 l), VE (+19±17 l*min-1) and BF (+8±6 min-1; all P<0.01)) and 
physical capacity (VO2max (+4.4±1.8 ml*min-1*kg-1), Wattmax (+35±11 W) and CO (+2.5±2.5 
ml*beat-1), all P<0.01), but showed no altered training response compared to CON. Four weeks 
of training pause showed no difference of detraining effect in parameters of physical capacity 
and lung function between CON and patients with T2D.
Conclusion:
In conclusion, 12-weeks HIIT improves physical and pulmonary performance in T2D and these 
changes show no difference compared to CON, even after 4 weeks of detraining.
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Background / Introduction:
Wasting is associated with increased adiponectin (ADN), an anti-inflammatory, insulin-sensitizing 
adipokine. Cystic fibrosis (CF) is a multi-organ disease characterized by inflammation, wasting 
and impaired insulin production. We assessed ADN and its high molecular weight (HMW) 
multimer form, and we measured venous plasma glucose (PG), serum insulin and free fatty acids 
(FFA) during an oral glucose tolerance test (oGTT) in patients with CF suffering from end stage 
lung disease.
Methods:
Over 10 years, consecutive CF patients were included and had evaluation with regard to lung 
transplantation. Patients (unless known for previous fasting PG (FPG) ≥7mM or insulin treatment, 
or on corticosteroids) and a control group of healthy subjects underwent an oGTT, and the 
insulinogenic index (IGI) was calculated as proposed by Wareham. Whole body and especially 
adipose tissue insulin sensitivity was estimated by calculating insulin resistance/sensitivity 
indices as proposed by Matthews (HOMA1-IR), Matsuda and DeFronzo (ISIcomp) and by Belfiore 
(ISIfat). ADN and its HMW form were measured by EIA, insulin by RIA, and FFA by a colorimetric 
assay. Data are expressed as mean±SD.
Results:
oGTT was performed in 47 CF patients (22 male; age 26±9y) and 34 controls (19 male; age 
31±10y). CF patients had lower BMI (18.6±3.5kg/m2) than the controls (23.5±4.4kg/m2). FPG, 
HOMA1-IR and ISIcomp were similar in patients and in controls. IGI was lower and the 2hPG was 
higher in CF patients than in controls (18.6±12.3 vs 62.2±39.2pM/mM; 10.1±4.5 vs 6.0±1.3mM). 
During oGTT, FFA decreased from 0.59±0.32 (fasting) to 0.13±0.09mM (after 2h) in CF patients 
and from 0.60±0.44 to 0.12±0.10mM in controls. ISIfat was 1.04±0.27 in CF patients and 1.00±0.34 
in controls. Total (and especially HMW-) ADN was higher in CF patients than in controls (10.4±3.8 
vs 7.9±3.5mg/l; HMW% of total, 51±10 vs 38±11). There was a positive correlation of total 
adiponectin and its HMW form (p<0.0001).
Conclusion:
ADN (particularly HMW-ADN) levels are higher in CF patients than in controls. Despite markedly 
impaired insulin secretion, FFA were suppressed to a similar extent in CF patients as in the 
controls. Residual insulin (in the face of apparently normal insulin sensitivity and in the context 
of increased energy expenditure) appears to be sufficient for maintaining FFA homeostasis in 
patients with CF.
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